Skip to main content
. 2013 Oct 17;109(10):2560–2565. doi: 10.1038/bjc.2013.605

Table 3. Toxicity (maximum grade per subject) by cohort in the phase 1 study of dose-escalated doxorubicin in cycles 1–3 ABVD.

  35 mg m2
 45 mg m2
 55 mg m2
  
  Grades 1-2 (%) Grades 3-4 (%) Grades 1-2 (%) Grades 3-4 (%) Grades 1-2 (%) Grades 3-4 (%) Published grades 3–5 toxicity rates with standard ABVD
Anaemia
 2 (33)
 0 (0)
 9 (75)
 1 (8)
 4 (66)
 0 (0)
 5%2
Neutropaenia
 2 (33)
 0 (0)
 5 (42)
 5 (42)
 1 (17)
 3 (50)
 34%2
Thrombocytopaenia
 1 (17)
 0 (0)
 1 (8)
 0 (0)
 1 (17)
 0 (0)
 3%2
Nausea
 4 (67)
 1 (17)
 9 (75)
 2 (17)
 6 (100)
 0 (0)
 13%2
Vomiting
 4 (67)
 1(17)
 8 (67)
 1 (8)
 5 (83)
 0 (0)
 13%2
Mucositis
 5 (83)
 0 (0)
 7 (58)
 0 (0)
 2 (33)
 0 (0)
 1–3%2,4
Diarrhoea
 4 (67)
 0 (0)
 7 (58)
 0 (0)
 2 (17)
 0 (0)
 —
Constipation
 5 (83)
 0 (0)
 11 (92)
 0 (0)
 5 (83)
 0 (0)
 2%2
Neuropathy
 4 (63)
 (0)
 9 (75)
 0 (0)
 4 (67)
 2 (33)
 0–3%2,4
Palmar Plantar Erythema (PPE)
 0 (0)
 0 (0)
 1 (8)
 0 (0)
 1 (17)
 2 (33)
 —
Pulmonary
 0 (0)
 0 (0)
 0 (0)
 2 (17)
 0 (0)
 1 (17)
 18–24.5%1,3
Infection
 3 (50)
 0 (0)
 7 (58)
 1 (8)
 3 (50)
 1 (17)
 2%
Fatigue
 3 (50)
 1 (17 )
 8 (75)
 0 (0)
 6 (100)
 0 (0)
 7%1
Other* 1(17) 0 (0) 2(17) 0(0) 2 (33) 0 (0) —

Abbreviation: ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine.

Other includes back pain, tumour pain, dyspnea, hearing impairment and palpitations.